High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

Douglas Gladstone, Kenneth W. Zamkoff, Lauren Krupp, Robert Peyster, Patrick Sibony, Christopher Christodoulou, Emily Locher, Patricia K. Coyle

Research output: Contribution to journalArticle

Abstract

Background: High-dose cyclophosphamide is active in immune-mediated illnesses. Objective: To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis. Design, Setting, and Patients: Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after 2 or more Food and Drug Administration-approved disease-modifying therapy regimens were evaluated. Interventions: Patients received 200 mg/kg of cyclophosphamide over 4 days. Main Outcome Measures: Patients had brain magnetic resonance imaging and neuro-ophthalmologic evaluations every 6 months and quarterly EDSS and quality-of-life evaluations for 2 years. Results: Twelve patients were evaluated for clinical response (median follow-up, 15.0 months; follow-up range, 6-24 months). During follow-up, no patients increased their baseline EDSS scores by more than 1.0. Five patients decreased their EDSS scores by 1.0 or more (EDSS score decrease range, 1.0-5.0). Two of 11 patients had a single enhancing lesion at baseline; these lesions resolved after high-dose cyclophosphamide treatment. At 12 months, 1 patient showed 1 new enhancing lesion without a corresponding high-intensity T2-weighted or fluid-attenuated inversion recovery signal. Patients reported improvement in all of the quality-of-life parameters measured. Neurologic improvement involved changes in gait, bladder control, and visual function. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. Patient quality-of-life improvement occurred independently of EDSS score changes. In this small group of patients with treatment-refractory multiple sclerosis, high-dose cyclophosphamide was associated with minimal morbidity and improved clinical outcomes. Conclusions: High-dose cyclophosphamide treatment in patients with severe refractory multiple sclerosis can result in disease stabilization, improved functionality, and improved quality of life. Further studies are necessary to determine the most appropriate patients for this treatment.

Original languageEnglish (US)
Pages (from-to)1388-1393
Number of pages6
JournalArchives of Neurology
Volume63
Issue number10
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Cyclophosphamide
Multiple Sclerosis
Quality of Life
Dose
Therapeutics
United States Food and Drug Administration
Quality Improvement
Gait
Nervous System
Urinary Bladder
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Morbidity

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Gladstone, D., Zamkoff, K. W., Krupp, L., Peyster, R., Sibony, P., Christodoulou, C., ... Coyle, P. K. (2006). High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Archives of Neurology, 63(10), 1388-1393. https://doi.org/10.1001/archneur.63.10.noc60076

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. / Gladstone, Douglas; Zamkoff, Kenneth W.; Krupp, Lauren; Peyster, Robert; Sibony, Patrick; Christodoulou, Christopher; Locher, Emily; Coyle, Patricia K.

In: Archives of Neurology, Vol. 63, No. 10, 2006, p. 1388-1393.

Research output: Contribution to journalArticle

Gladstone, D, Zamkoff, KW, Krupp, L, Peyster, R, Sibony, P, Christodoulou, C, Locher, E & Coyle, PK 2006, 'High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis', Archives of Neurology, vol. 63, no. 10, pp. 1388-1393. https://doi.org/10.1001/archneur.63.10.noc60076
Gladstone, Douglas ; Zamkoff, Kenneth W. ; Krupp, Lauren ; Peyster, Robert ; Sibony, Patrick ; Christodoulou, Christopher ; Locher, Emily ; Coyle, Patricia K. / High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. In: Archives of Neurology. 2006 ; Vol. 63, No. 10. pp. 1388-1393.
@article{0887868fc92e4ca897348da4785fcc8f,
title = "High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis",
abstract = "Background: High-dose cyclophosphamide is active in immune-mediated illnesses. Objective: To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis. Design, Setting, and Patients: Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after 2 or more Food and Drug Administration-approved disease-modifying therapy regimens were evaluated. Interventions: Patients received 200 mg/kg of cyclophosphamide over 4 days. Main Outcome Measures: Patients had brain magnetic resonance imaging and neuro-ophthalmologic evaluations every 6 months and quarterly EDSS and quality-of-life evaluations for 2 years. Results: Twelve patients were evaluated for clinical response (median follow-up, 15.0 months; follow-up range, 6-24 months). During follow-up, no patients increased their baseline EDSS scores by more than 1.0. Five patients decreased their EDSS scores by 1.0 or more (EDSS score decrease range, 1.0-5.0). Two of 11 patients had a single enhancing lesion at baseline; these lesions resolved after high-dose cyclophosphamide treatment. At 12 months, 1 patient showed 1 new enhancing lesion without a corresponding high-intensity T2-weighted or fluid-attenuated inversion recovery signal. Patients reported improvement in all of the quality-of-life parameters measured. Neurologic improvement involved changes in gait, bladder control, and visual function. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. Patient quality-of-life improvement occurred independently of EDSS score changes. In this small group of patients with treatment-refractory multiple sclerosis, high-dose cyclophosphamide was associated with minimal morbidity and improved clinical outcomes. Conclusions: High-dose cyclophosphamide treatment in patients with severe refractory multiple sclerosis can result in disease stabilization, improved functionality, and improved quality of life. Further studies are necessary to determine the most appropriate patients for this treatment.",
author = "Douglas Gladstone and Zamkoff, {Kenneth W.} and Lauren Krupp and Robert Peyster and Patrick Sibony and Christopher Christodoulou and Emily Locher and Coyle, {Patricia K.}",
year = "2006",
doi = "10.1001/archneur.63.10.noc60076",
language = "English (US)",
volume = "63",
pages = "1388--1393",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

AU - Gladstone, Douglas

AU - Zamkoff, Kenneth W.

AU - Krupp, Lauren

AU - Peyster, Robert

AU - Sibony, Patrick

AU - Christodoulou, Christopher

AU - Locher, Emily

AU - Coyle, Patricia K.

PY - 2006

Y1 - 2006

N2 - Background: High-dose cyclophosphamide is active in immune-mediated illnesses. Objective: To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis. Design, Setting, and Patients: Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after 2 or more Food and Drug Administration-approved disease-modifying therapy regimens were evaluated. Interventions: Patients received 200 mg/kg of cyclophosphamide over 4 days. Main Outcome Measures: Patients had brain magnetic resonance imaging and neuro-ophthalmologic evaluations every 6 months and quarterly EDSS and quality-of-life evaluations for 2 years. Results: Twelve patients were evaluated for clinical response (median follow-up, 15.0 months; follow-up range, 6-24 months). During follow-up, no patients increased their baseline EDSS scores by more than 1.0. Five patients decreased their EDSS scores by 1.0 or more (EDSS score decrease range, 1.0-5.0). Two of 11 patients had a single enhancing lesion at baseline; these lesions resolved after high-dose cyclophosphamide treatment. At 12 months, 1 patient showed 1 new enhancing lesion without a corresponding high-intensity T2-weighted or fluid-attenuated inversion recovery signal. Patients reported improvement in all of the quality-of-life parameters measured. Neurologic improvement involved changes in gait, bladder control, and visual function. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. Patient quality-of-life improvement occurred independently of EDSS score changes. In this small group of patients with treatment-refractory multiple sclerosis, high-dose cyclophosphamide was associated with minimal morbidity and improved clinical outcomes. Conclusions: High-dose cyclophosphamide treatment in patients with severe refractory multiple sclerosis can result in disease stabilization, improved functionality, and improved quality of life. Further studies are necessary to determine the most appropriate patients for this treatment.

AB - Background: High-dose cyclophosphamide is active in immune-mediated illnesses. Objective: To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis. Design, Setting, and Patients: Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after 2 or more Food and Drug Administration-approved disease-modifying therapy regimens were evaluated. Interventions: Patients received 200 mg/kg of cyclophosphamide over 4 days. Main Outcome Measures: Patients had brain magnetic resonance imaging and neuro-ophthalmologic evaluations every 6 months and quarterly EDSS and quality-of-life evaluations for 2 years. Results: Twelve patients were evaluated for clinical response (median follow-up, 15.0 months; follow-up range, 6-24 months). During follow-up, no patients increased their baseline EDSS scores by more than 1.0. Five patients decreased their EDSS scores by 1.0 or more (EDSS score decrease range, 1.0-5.0). Two of 11 patients had a single enhancing lesion at baseline; these lesions resolved after high-dose cyclophosphamide treatment. At 12 months, 1 patient showed 1 new enhancing lesion without a corresponding high-intensity T2-weighted or fluid-attenuated inversion recovery signal. Patients reported improvement in all of the quality-of-life parameters measured. Neurologic improvement involved changes in gait, bladder control, and visual function. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. Patient quality-of-life improvement occurred independently of EDSS score changes. In this small group of patients with treatment-refractory multiple sclerosis, high-dose cyclophosphamide was associated with minimal morbidity and improved clinical outcomes. Conclusions: High-dose cyclophosphamide treatment in patients with severe refractory multiple sclerosis can result in disease stabilization, improved functionality, and improved quality of life. Further studies are necessary to determine the most appropriate patients for this treatment.

UR - http://www.scopus.com/inward/record.url?scp=33749627690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749627690&partnerID=8YFLogxK

U2 - 10.1001/archneur.63.10.noc60076

DO - 10.1001/archneur.63.10.noc60076

M3 - Article

VL - 63

SP - 1388

EP - 1393

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 10

ER -